Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

Unzu C, Hervás-Stubbs S, Sampedro A, Mauleón I, Mancheño U, Alfaro C, de Salamanca RE, Benito A, Beattie SG, Petry H, Prieto J, Melero I, Fontanellas A.

J Transl Med. 2012 Jun 15;10:122. doi: 10.1186/1479-5876-10-122.

2.

Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.

McIntosh JH, Cochrane M, Cobbold S, Waldmann H, Nathwani SA, Davidoff AM, Nathwani AC.

Gene Ther. 2012 Jan;19(1):78-85. doi: 10.1038/gt.2011.64. Epub 2011 Jun 30.

3.

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, Zhou S, Wright JF, Jiang H, Pierce GF, Arruda VR, High KA.

Blood. 2007 Oct 1;110(7):2334-41. Epub 2007 Jul 3.

4.

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, Zhou S, Scallan CD, Sommer J, Vijay S, Mingozzi F, High KA, Pierce GF.

Blood. 2006 Nov 15;108(10):3321-8. Epub 2006 Jul 25.

5.

Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates.

Fontanellas A, Hervás-Stubbs S, Mauleón I, Dubrot J, Mancheño U, Collantes M, Sampedro A, Unzu C, Alfaro C, Palazón A, Smerdou C, Benito A, Prieto J, Peñuelas I, Melero I.

Mol Ther. 2010 Apr;18(4):754-65. doi: 10.1038/mt.2009.312. Epub 2010 Jan 19.

6.

Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria.

Pañeda A, Lopez-Franco E, Kaeppel C, Unzu C, Gil-Royo AG, D'Avola D, Beattie SG, Olagüe C, Ferrero R, Sampedro A, Mauleon I, Hermening S, Salmon F, Benito A, Gavira JJ, Cornet ME, del Mar Municio M, von Kalle C, Petry H, Prieto J, Schmidt M, Fontanellas A, González-Aseguinolaza G.

Hum Gene Ther. 2013 Dec;24(12):1007-17. doi: 10.1089/hum.2013.166.

PMID:
24070415
7.

Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.

Rivière C, Danos O, Douar AM.

Gene Ther. 2006 Sep;13(17):1300-8. Epub 2006 May 11.

PMID:
16688207
8.

Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.

Unzu C, Melero I, Hervás-Stubbs S, Sampedro A, Mancheño U, Morales-Kastresana A, Serrano-Mendioroz I, de Salamanca RE, Benito A, Fontanellas A.

Gene Ther. 2015 Nov;22(11):856-65. doi: 10.1038/gt.2015.64. Epub 2015 Jul 23.

PMID:
26125605
9.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2007 Oct;7(5):316-24. Review.

PMID:
17979678
10.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2011 Aug;11(4):321-30. Review.

PMID:
21557723
11.

Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.

Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, Poutou J, Fortes P, Mancheno U, Bunuales M, Olagüe C, Razquin N, Van Rooijen N, Enguita M, Hernandez-Alcoceba R.

Liver Int. 2015 Apr;35(4):1274-89. doi: 10.1111/liv.12571. Epub 2014 May 10.

PMID:
24754307
12.

Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.

Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW.

Mol Vis. 2008 Sep 24;14:1760-9.

13.

Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.

Mingozzi F, Chen Y, Murphy SL, Edmonson SC, Tai A, Price SD, Metzger ME, Zhou S, Wright JF, Donahue RE, Dunbar CE, High KA.

Mol Ther. 2012 Jul;20(7):1410-6. doi: 10.1038/mt.2012.84. Epub 2012 May 8.

14.

Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.

Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA.

Mol Med. 1997 Dec;3(12):813-25.

15.

Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways.

Sumner-Jones SG, Davies LA, Varathalingam A, Gill DR, Hyde SC.

Gene Ther. 2006 Dec;13(24):1703-13. Epub 2006 Jul 20.

PMID:
16855618
16.

Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.

Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K.

J Virol. 2001 Jan;75(1):269-77.

17.

Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.

Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V.

Hum Gene Ther. 1998 Mar 1;9(4):477-85.

PMID:
9525309
18.

Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors.

Montenegro-Miranda PS, ten Bloemendaal L, Kunne C, de Waart DR, Bosma PJ.

Hum Gene Ther. 2011 May;22(5):605-12. doi: 10.1089/hum.2010.222. Epub 2011 Apr 11.

PMID:
21222531
19.

Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates.

Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, Figueredo J, Lock M, Wilson JM.

Mol Ther. 2006 Jan;13(1):77-87. Epub 2005 Oct 10. Erratum in: Mol Ther. 2006 Jul;14(1):150.

PMID:
16219492
20.

Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer.

Ogura T, Mizukami H, Mimuro J, Madoiwa S, Okada T, Matsushita T, Urabe M, Kume A, Hamada H, Yoshikawa H, Sakata Y, Ozawa K.

J Gene Med. 2006 Aug;8(8):990-7.

PMID:
16685745
Items per page

Supplemental Content

Write to the Help Desk